Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02160262 · ClinicalTrials.gov registry record · Phase 3
Open-label Safety Study in Adults With ADHD
A Phase 3 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 724
- Enrollment target
NCT02160262: Completed Phase 3 study, sponsored by Sumitomo Pharma America.
NCT02160262 is a Phase 3 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 724 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02160262, a Phase 3 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 724 participants
- Enrollment target
Study Summary
To evaluate the long-term safety and tolerability of SEP 225289 in adult subjects with Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
- DRUG Dasotraline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 724 participants |
| Start Date | 2014-06 |
| Est. Completion | 2016-05 |
| Phase | Phase 3 |
What the finished NCT02160262 record still lists
NCT02160262 is an interventional study that assigns participants to a tested intervention. The registered 724 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which Dasotraline is the first listed.
NCT02160262 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02160262 about?
NCT02160262 is a clinical study titled "Open-label Safety Study in Adults With ADHD". To evaluate the long-term safety and tolerability of SEP 225289 in adult subjects with Attention Deficit Hyperactivity Disorder (ADHD)
What is the current status of trial NCT02160262?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 724 participants. The study started on 2014-06. Estimated completion is 2016-05.
What interventions are being tested in trial NCT02160262?
The interventions under investigation include: Dasotraline (DRUG).
Who is sponsoring clinical trial NCT02160262?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02160262's enrollment target sits among peer trials
724 491st of 2000 higher than 1,509 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06664619 · 724 participants · Phase 3
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
- NCT05634967 · 725 participants
Kesimpta (Ofatumumab) Pregnancy Registry
- NCT06641466 · 723 participants · Phase 3
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
- NCT07088068 · 723 participants · Phase 3
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia